Adaptive Biotechnologies (1HM) Stock Overview
A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
1HM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Adaptive Biotechnologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.35 |
| 52 Week High | US$17.71 |
| 52 Week Low | US$5.70 |
| Beta | 2.18 |
| 1 Month Change | -11.65% |
| 3 Month Change | 10.70% |
| 1 Year Change | 70.11% |
| 3 Year Change | 53.10% |
| 5 Year Change | -70.33% |
| Change since IPO | -59.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1HM | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 1.8% | -3.2% | -0.3% |
| 1Y | 70.1% | -20.9% | 4.5% |
Return vs Industry: 1HM exceeded the German Life Sciences industry which returned -22.3% over the past year.
Return vs Market: 1HM exceeded the German Market which returned 4% over the past year.
Price Volatility
| 1HM volatility | |
|---|---|
| 1HM Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 13.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 1HM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1HM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 619 | Chad Robins | www.adaptivebiotech.com |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).
Adaptive Biotechnologies Corporation Fundamentals Summary
| 1HM fundamental statistics | |
|---|---|
| Market cap | €2.08b |
| Earnings (TTM) | -€50.21m |
| Revenue (TTM) | €233.74m |
Is 1HM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1HM income statement (TTM) | |
|---|---|
| Revenue | US$276.98m |
| Cost of Revenue | US$165.13m |
| Gross Profit | US$111.85m |
| Other Expenses | US$171.35m |
| Earnings | -US$59.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 40.38% |
| Net Profit Margin | -21.48% |
| Debt/Equity Ratio | 58.3% |
How did 1HM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/17 12:59 |
| End of Day Share Price | 2026/02/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adaptive Biotechnologies Corporation is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |